Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | CXCR4 | P61073 | 14/20 | 0.74 |
| ▸ | EBP | Q15125 | 1/20 | 0.71 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.71 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7614548 | 1.00 | MEN1 (1.00) | MEN1TP53CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL29373593 | 1.00 | MEN1 (1.00) | MEN1TP53CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL7920925 | 0.98 | MEN1 (0.96) | MEN1TP53CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL30545887 | 0.98 | MEN1 (0.96) | MEN1TP53CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL7920921 | 0.98 | MEN1 (0.96) | MEN1TP53CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL3675376 | 0.96 | MEN1 (0.93) | MEN1TP53CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5322402 | 0.91 | MEN1 (0.84) | MEN1TP53CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1966295 | 0.82 | MEN1 (0.70) | MEN1TP53CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6072254 | 0.80 | CHRM2 (0.72) | MEN1TP53CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL25378299 | 0.78 | MEN1 (0.64) | MEN1TP53CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0841909-B1 | USE OF ALICYCLIC DIAMINES AS IMMUNOMODULATORS | NEOVACS (FR) | 2002-03-13 | — | — | EP | claimed |
| US-20240245703-A1 | TOPICAL APPLICATION OF AGENTS TO REDUCE SUN SENSITIVITY AND IMPROVE TOPICAL PHOTODYNAMIC THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-07-25 | — | — | US | disclosed |
| WO-2023053097-A1 | TOPICAL APPLICATION OF AGENTS TO REDUCE SUN SENSITIVITY AND IMPROVE TOPICAL PHOTODYNAMIC THERAPY | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2023-04-06 | — | — | WO | disclosed |
| US-9427431-B2 | Inhibitors of hedgehog signaling pathways, compositions and uses related thereto | JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2016-08-30 | — | — | US | disclosed |
| EP-1067939-B1 | USE OF STEROIDAL ALKALOID DERIVATIVES AS INHIBITORS OF HEDGEHOG PROTEIN SIGNALING PATHWAYS | UNIV JOHNS HOPKINS (US) | 2015-09-16 | — | — | EP | disclosed |
| EP-1879877-B1 | ANTIMICROBIAL AGENTS | RANBAXY LAB LTD (IN) | 2013-01-02 | — | — | EP | disclosed |
| US-20120183603-A1 | INHIBITORS OF HEDGEHOG SIGNALING PATHWAYS, COMPOSITIONS AND USES RELATED THERETO | BEACHY PHILIP A (US) | 2012-07-19 | — | — | US | disclosed |
| US-8097632-B2 | Blocking hedgehog protein transduction signal passageway using alkaloid steroid | JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2012-01-17 | — | — | US | disclosed |
| US-7998946-B2 | Veratrum-type alkaloid inhibits mitotic cell proliferation in hedgehog-mediated signal transduction with an ED50 of 1 mM or less; preparations administered systemically, locally, topically; cancer; non-malignant hyperproliferative disorders | JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2011-08-16 | — | — | US | disclosed |
| US-20090306134-A1 | Muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-12-10 | — | — | US | disclosed |
| US-7291626-B1 | Inhibitors of hedgehog signaling pathways, compositions and uses related thereto | JOHN HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2007-11-06 | — | — | US | disclosed |
| US-20070179179-A1 | Beta2-adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-08-02 | — | — | US | disclosed |
| US-20070179179-A1 | Beta2-adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-08-02 | — | — | US | disclosed |
| US-7217738-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-7217738-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-7211695-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| US-7211695-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| US-7179794-B2 | Multivalent macrolide antibiotics | THERAVANCE, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-7173039-B2 | Protein kinase inhibitors | THERAVANCE, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173039-B2 | Protein kinase inhibitors | THERAVANCE, INC. (US) | 2007-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120183603-A1 | INHIBITORS OF HEDGEHOG SIGNALING PATHWAYS, COMPOSITIONS AND USES RELATED THERETO | SHH, GLI1, SMO | MEN1 923/4885TP53 2285/4885CYP3A4 4782/4885 |
| US-20090306134-A1 | Muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | MEN1 3774/4885TP53 4086/4885CYP3A4 2099/4885 |
| US-20070179179-A1 | Beta2-adrenergic receptor agonists | ADRB2, ADRB1, ADRA2B | MEN1 4705/4885TP53 4879/4885CYP3A4 1760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.